Now showing items 1-8 of 8

    • Can the United States Afford a "No-Fault" System of Compensation for Medical Injury? 

      Studdert, David Michael; Thomas, Eric J.; Zbar, Brett I.W.; Newhouse, Joesph P.; Weiler, Paul Cronin; Bayuk, Jonathon; Brennan, Troyen Anthony (Duke University School of Law, 1997)
      One of the key issues separating US critics of a no-fault alternative to the tort system for compensating victims of medical injury from supporters is its anticipated cost. Results from a study are presented that estimate ...
    • Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes 

      Gagne, Joshua J; Choudhry, Niteesh Kumar; Kesselheim, Aaron Seth; Polinski, Jennifer Milan; Hutchins, David; Matlin, Olga S.; Brennan, Troyen Anthony; Avorn, Jerry Lewis; Shrank, William (American College of Physicians, 2014)
      Background: Statins are effective in preventing cardiovascular events, but patients do not fully adhere to them. Objective: To determine whether patients are more adherent to generic statins versus brand-name statins ...
    • Comparative effectiveness of generic versus brand-name antiepileptic medications 

      Gagne, Joshua J; Kesselheim, Aaron Seth; Choudhry, Niteesh Kumar; Polinski, Jennifer Milan; Hutchins, David; Matlin, Olga S.; Brennan, Troyen Anthony; Avorn, Jerry Lewis; Shrank, William (Elsevier BV, 2015)
      OBJECTIVE: The objective of this study was to compare treatment persistence and rates of seizure-related events in patients who initiate antiepileptic drug (AED) therapy with a generic versus a brand-name product. METHODS: ...
    • Equity in the Receipt of Oseltamivir in the United States During the H1N1 Pandemic 

      Franklin, Jessica Myers; Choudhry, Niteesh Kumar; Uscher-Pines, Lori; Brill, Gregory; Matlin, Olga S.; Fischer, Michael Adam; Schneeweiss, Sebastian; Avorn, Jerry Lewis; Brennan, Troyen Anthony; Shrank, William (American Public Health Association, 2014)
      Objectives. We assessed the relationship between individual characteristics and receipt of oseltamivir (Tamiflu) in the United States during the H1N1 pandemic and other flu seasons. Methods. In a cohort of individuals ...
    • Five Features Of Value-Based Insurance Design Plans Were Associated With Higher Rates Of Medication Adherence 

      Choudhry, Niteesh Kumar; Fischer, Michael Adam; Smith, B. F.; Brill, G.; Girdish, C.; Matlin, O. S.; Brennan, Troyen Anthony; Avorn, Jerry Lewis; Shrank, W (Health Affairs (Project Hope), 2014)
      Value-based insurance design (VBID) plans selectively lower cost sharing to increase medication adherence. Existing plans have been structured in a variety of ways, and these variations could influence the effectiveness ...
    • Improving the Postmarket Surveillance of Total Joint Arthroplasty Devices 

      Mahomed, Nizar N; Syed, Khalid; Sledge, Clement Blount; Brennan, Troyen Anthony; Liang, Matthew Heng (Bentham Science Publishers Ltd., 2008)
      Objective: To evaluate the FDA’s approval process and postmarket surveillance strategies for THR devices. Design: The FDA Center for Devices and Radiological Health (CDRH) 510k releasable database was used to document ...
    • Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation— Quality and Cost Implications 

      Desai, Nihar R.; Krumme, Alexis A.; Schneeweiss, Sebastian; Shrank, William; Brill, Gregory; Pezalla, Edmund J.; Spettell, Claire M.; Brennan, Troyen Anthony; Matlin, Olga S.; Avorn, Jerry Lewis; Choudhry, Niteesh Kumar (Elsevier BV, 2014)
      Background. Dabigatran, rivaroxaban, and apixaban have been approved for use in patients with atrial fibrillation based upon randomized trials demonstrating their comparable or superior efficacy and safety relative to ...
    • Time series analyses of the effect of FDA communications on use of prescription weight loss medications 

      Block, Jason Perry; Choudhry, Niteesh Kumar; Carpenter, Daniel Paul; Fischer, Michael Adam; Brennan, Troyen Anthony; Tong, A. Y.; Matlin, O. S.; Shrank, W (Wiley-Blackwell, 2014)
      OBJECTIVE: To determine the impact of FDA safety communications regarding the weight loss medications sibutramine and orlistat. METHODS: The 2008 to 2011 pharmacy claims data from CVS Caremark were used to determine the ...